Category Archives: Immunology

Immunology

Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience – Nasdaq

Roche Holdings(OTCMKTS:RHHBY) revenue grew at a CAGR of 5.3% from $52.5 billion in 2015 to $64.4 billion in 2019, and it is estimated to top $66 billion in 2020, led by its Neuroscience drugs. The companys oncology drugs will account for 45% of the companys total sales in 2020, but Neuroscience drugs are key to the near term revenue growth, in our view.Oncology drugs are expected to be the single-biggest revenue driver with $30.1 billion in revenues (45% of Total Revenues), which is 5.7x the size of its Neuroscience drugs revenue in 2020. Neuroscience drugs revenues, which includes Ocrevus and Modopar among other drugs, will be the fastest-growing segment adding $3.7 billion over 2017-2020 (32% of $11.6 billion in incremental revenues). Oncology drugs revenues, which includes Herceptin, Perjeta, Tecentriq, and Avastin among other drugs, will add about $3.4 billion over 2017-2020 (29% of the $11.6 billion in incremental revenue). Look at our interactive dashboard analysis on Roches Revenues for more details, parts of which are highlighted below.

Roches Revenue Has Been On A Rise Over The Last Few Years

Comparing Roches Sales Growth To Its Peers

Roche Has One of The Largest Oncology Drugs Portfolio, But It Is Expected To See A Decline Going Forward.

Ocrevus Has Been The Best Drug Launch Ever For Roche, Boosting Its Neuroscience Drugs Portfolio

Other Therapeutic Drugs Could Also See Growth In The Near Term

Among Other Segments, In-Vitro Diagnostics Could Continue To Grow At A Steady Pace, While Immunology, Ophthalmology, And Virology Drugs Could See A Decline

See allTrefis Price EstimatesandDownloadTrefis Datahere

Whats behind Trefis? See How Its Powering New Collaboration and What-Ifs ForCFOs and Finance Teams|Product, R&D, and Marketing Teams

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read more:
Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience - Nasdaq

Immunology

New immune cell with ‘Jekyll and Hyde properties’ identified – The Medical News

Scientists at Trinity College Dublin have identified a rare, new cell in the immune system with "Jekyll and Hyde properties". These cells play a key protective role in immunity to infection but - if unregulated - also mediate tissue damage in autoimmune disorders.

The findings should help us design more effective vaccines to prevent infections such as MRSA, and may also assist help us develop of new therapies for autoimmune diseases, such as multiple sclerosis or rheumatoid arthritis.

The research was funded by Science Foundation Ireland and led by Kingston Mills, Professor of Experimental Immunology, and Dr. Sarah Edwards and Dr. Caroline Sutton, Postdoctoral Fellows in the School of Biochemistry and Immunology in the Trinity Biomedical Sciences Institute. Their findings were published today [Thursday 27th February 2020] in The Journal of Experimental Medicine.

The immune system functions to control infection, utilizing various immune cells, such as T cells to respond to and control invading microbes. However, if these immune cells are not highly regulated, they can attack and damage body tissues, leading to the development of autoimmune diseases.

Molecules called T cell receptors (TCRs) allow T cells to recognize components of infectious agents with exquisite specificity. The TCRs enable T cells to respond to and eventually eliminate the infectious agent.

Professor Kingston Mills said:

Until now scientists thought that there were two discrete populations of T cells, expressing either '' or '' TCRs. The s are the most common T cells in the body. They play a key role in remembering prior infection or immunization and thereby help protect us against re-infection and mediate vaccine-induced protective immunity. The s are more prevalent at mucosal surfaces, such as the lung or gut, and provide an immediate first line of defense against pathogens that invade through these routes."

We have discovered a new cell type that expresses both and TCRs. This rare population of chimeric or hybrid - T cells has properties of both and T cells. Importantly, they are normally highly activated and poised to act as first responders to control bacterial infection. However, given this high level of activation, they are effectively 'Jekyll and Hyde cells' because in certain contexts they can also precipitate autoimmune responses."

Using a model of Staphylococcus aureus infection, Professor Mills and his team found that these cells are rapidly mobilized during infection and play a key role in quickly eliminating the microbes from the body.

The induction of these hybrid - T cells may thus represent a novel approach in the design of more effective vaccines against Staph aureus and other infectious diseases, while advancing our ability to control their response may yield additional therapeutic options.

Professor Mills added:

In a model of autoimmune disease, we found that the hybrid T cells can also trigger the inflammatory cascade that mediates tissue damage in autoimmunity. Therefore, approaches for inhibiting these highly activated immune cells in susceptible individuals may open up new approaches for the treatment of autoimmune diseases such as psoriasis and multiple sclerosis."

Visit link:
New immune cell with 'Jekyll and Hyde properties' identified - The Medical News

Immunology

Does the Drug Used in Anesthesia Contain Egg and Soy? – Allergic Living

11

Published:February 28, 2020

Q: Our teenage daughter with egg and soy allergies has to have surgery. Ive been told that the drug propofol used in anesthesia contains both egg and soy. Is that correct and should I be concerned?

Dr. Sharma: Propofol is mixed in a liquid which contains soybean oil and egg lecithin (a fatty substrate).

For people like your daughter, who have soy or egg allergies, they are allergic to the proteins in these foods, not the oils or fats.

While in theory soy oil and egg lecithin might contain trace amounts of protein, there are no reports in the medical literature of any allergic reactions caused by these ingredients.

There have been reports of allergic reactions to propofol in medical literature. But none of these appear to be related to soy or egg allergy.

Therefore, the general recommendation is that patients who require anesthesia with soy or egg allergy can receive propofol. But be sure to check with your daughters allergist to discuss her particular case.

Dr. Sharma is an allergist, clinical researcher andassociateprofessor of pediatrics. He isChiefof the Division of Allergy and Immunology at Childrens National Medical Center in Washington D.C. and Director of the Food Allergy Program. He co-authors The Food Allergy Experts column inAllergic Livings e-magazine. Questions submitted will be considered for answer in the e-magazine.

Related:The Truth About Drug AllergiesTop Allergens: Places Where They HideFood Allergies and Hospitals: Lack of Training and Reliable Systems

Here is the original post:
Does the Drug Used in Anesthesia Contain Egg and Soy? - Allergic Living

Immunology

Harbour BioMed Announces US FDA Approval of IND for Its Next Generation anti-CTLA-4 Antibody, HBM4003, to Treat Cancer – BioSpace

Feb. 28, 2020 11:00 UTC

First fully human, heavy chain only antibody in human trials has shown potent activity in preclinical studies through differentiated mechanism of action

CAMBRIDGE, Mass. & ROTTERDAM, Netherlands & SUZHOU, China--(BUSINESS WIRE)-- Harbour Biomed (HBM) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application to begin clinical studies with HBM4003, its next generation anti-CTLA-4 antibody for the treatment of cancer. The U.S. study builds on an initial ongoing trial in Australia. The trial will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM4003 as a single agent in subjects with advanced solid tumors.

The IND approval is an important next step in our global program to develop this exciting molecule, said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. In preclinical studies, HBM4003 demonstrated potent anti-tumor activity based on a differentiated mechanism of action and a favorable safety profile. HBM4003 is the first in a portfolio of mono- and bi-specific antibodies based on our patented, heavy chain only (HCAb) technology against various immuno-oncology and immunology targets that are advancing toward clinical trials.

About HBM4003 HBM4003 is the fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice. HBM4003 shows enhanced antibody-dependent cell cytotoxicity (ADCC) killing activity and is extremely specific to CTLA-4High Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug.

About Harbour BioMed Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases. The company is building its proprietary pipeline through internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.

The company's internal discovery programs are centered around its two patented transgenic mouse platforms (Harbour Mice) for generating both fully human monoclonal antibodies and heavy chain only antibodies (HCAb) based immune cell engager (HBICE) bispecific antibodies. Harbour BioMed also licenses the platforms to companies and academic institutions. The company has operations in Cambridge, Massachusetts; Rotterdam, The Netherlands; and Suzhou & Shanghai, China.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200228005075/en/

Follow this link:
Harbour BioMed Announces US FDA Approval of IND for Its Next Generation anti-CTLA-4 Antibody, HBM4003, to Treat Cancer - BioSpace

Immunology

Cuba develops new drugs against cancer and other diseases – OnCubaNews

Cuban scientists are working on several new drugs against cancer and other diseases, such as cardiovascular ailments and rheumatoid arthritis, Granma newspaper reported.

The BioCubaFarma group is currently carrying out 102 projects, of which 75 have a Cuban patent, explained Rolando Prez, director of Science and Innovation of this state conglomerate dedicated to the production of medicines, medical equipment and high-tech services.

The HerberSavax therapeutic vaccineone of the leading products in the oncology areais in phase III clinical trials in ovarian tumors and hepatocarcinoma, which is the most common type of liver cancer.

Developed by the Center for Genetic Engineering and Biotechnology (CIGB), a leading entity in this field on the island, the vaccine reduces the formation of blood vessels in the tumor, thereby limiting the supply of nutrients and oxygen and inhibiting its growth and shows encouraging results in some patients.

Cuba prueba una nueva vacuna contra tumores slidos

For its part, a biopharmaceutical created at the Molecular Immunology Center is about to begin a phase I clinical trial in patients with solid tumors. According to Prez, it is a product of the field of cancer immunotherapy, in which intensive research is being carried out.

We have five other products in development in the initial stages of clinical trials, of which two are therapeutic vaccines, two antitumor peptides and a monoclonal antibody, he told Granma.

The director of Science and Innovation of BioCubaFarma also referred to a novel drug, the immunomodulatory peptide called cigb814, to treat patients with rheumatoid arthritis, a disease that causes a high degree of disability.

Another product being developed is the cigb500 peptide, which has shown a powerful cardioprotective activity, according to the specialist.

The phase I clinical trial demonstrated the safety of the drug. A phase II clinical trial is currently underway in patients with acute myocardial infarction, whose results should be ready in the second half of the year, said Prez.

Empresa farmacutica cubana niega despidos masivos

Founded in 2012 and made up of about thirty companies, BioCubaFarma manufactures and distributes more than 1,000 products, 482 of which are included in Cubas basic medicine chart, and its products are exported to more than 50 countries.

In general, biotechnology products and the pharmaceutical industry are among Cubas main exportable items. Among its most recognized medicines are Heberprot-P, a successful therapy to treat diabetic foot ulcers registered in more than 20 countries, of which Havanas CIGB is now working on new formulations.

In addition, the CIMAVAX-EGF vaccine against lung cancer and the Heberferon for the treatment of skin cancer, as well as vaccines against hepatitis B and meningitis and the recombinant Interferon alfa 2B antiviral (IFNrec), which is among the drugs chosen by China to treat COVID-19 coronavirus.

See more here:
Cuba develops new drugs against cancer and other diseases - OnCubaNews

Immunology

Swedish Orphan Biovitrum : New research uncovers the toll rare diseases take on relationships – marketscreener.com

According to a new survey from rare disease company Sobi, 28 per cent of people living with a rare condition, and their caregivers, say the disease has caused a relationship to end. 41 percent state that a rare disease has prevented them from starting a new romantic relationship.

There are approximately 6,700 rare diseases affecting fewer than 1 out of 2,000 people. Approximately 350 million people around the world are diagnosed with one or more rare diseases (1)."This is the first time we have studied how rare diseases can affect relationships. We know that close relationships are a vital part of life and we believe that is particularly relevant for people living with a rare condition," said Jennifer Cain Birkmose, Global Head of Patient Access and Community Engagement at Sobi.

28 percent of the respondents in Sobi's study said a rare disease was the reason a relationship ended. Almost half (43 percent) said the disease has been a barrier in all their relationships, either romantic or friendship. 41 percent believed the disease has prevented them from starting a new romantic relationship.

Cain Birkmose said that the study results also highlight the effect on the people closest to those living with a rare disease.

"It's important to keep in mind that broader networks of family, friends and care teams are also impacted. Rare Disease Day is a reminder to listen closely to the rare disease community to gain a deeper understanding of their needs, so we can then work together to raise awareness and improve treatment possibilities," she said.

About the study

The survey was conducted online in the USA, Italy, Germany, Spain, Sweden and the UK among patients and caregivers Patients had to have a rare medical condition from the National Organisation for Rare Disorders list(https://rarediseases.org/for-patients-and-families/information-resources/rare-disease-information/). Caregivers had to be caring for someone with a rare medical condition from the NORD list Fieldwork took place from the 5[th] until the 13[th] February and 200 interviews were conducted in total Research was conducted on behalf of Sobi by Phoenix Marketing International

For more informationRare Disease Day: http://www.rarediseaseday.orgRare diseases: https://www.rarediseaseday.org/article/what-is-a-rare-disease

About SobiSobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,300 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi's revenues amounted to SEK 14.2 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

For more information please contact

Paula Treutiger, Head of Communication & Investor Relations+ 46 733 666 599paula.treutiger@sobi.com

Linda Holmstrm, Corporate Communication & Investor Relations+ 46 708 734 095linda.holmstrom@sobi.com

(1)www.agrenska.se/Sallsynta-diagnoser/

Swedish Orphan Biovitrum AB (publ)Postal address SE-112 76 Stockholm, SwedenPhone: 46 8 697 20 00 http://www.sobi.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/new-research-uncovers-the-toll-rare-diseases-take-on-relationships,c3048426

https://mb.cision.com/Main/14266/3048426/1202450.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

Follow this link:
Swedish Orphan Biovitrum : New research uncovers the toll rare diseases take on relationships - marketscreener.com

Immunology

Allergists Offer Advice to Parents of Kids With Food Allergies – The New York Times

The allergists also talked about creating thoughtful and balanced communication, having credible health information to share with children, and supporting a positive feedback loop between parents and children rather than one that builds anxiety. "Parents should be encouraged to transfer their knowledge to children, not all of their worries," one expert remarked.

"Psychosocial coping with food allergies can be understood and managed when clear communication is present between parents and children and between healthcare providers and patients," Gupta said. "It is a balance between lots of sound medical information and a good understanding of a child's risks and coping resources."

Coping is often impeded by misinformation about food allergies, the experts said, so it's important for parents to receive consistent messaging and counseling for the family, if necessary.

"You are taking care of the kids, but you are (also) managing the family unit, as you should be," one allergist said.

Brochures, apps, virtual groups and other educational materials can offer scientifically informed resources for parents and kids to manage food allergies. Gupta and colleagues are now collecting information in an online survey about the coping strategies and integrative medicine that parents and children have used.

"It's important for families to know that it's normal to be stressed about food allergy and feel overwhelmed, worried, sad or frustrated at times," said Linda Herbert, director of the Psychosocial Services Program for the Division of Allergy and Immunology at Children's National Hospital in Washington, D.C.

"But it's equally important to know that they can get help from a professional," Herbert, who wasn't involved in the study, told Reuters Health by email. "The mental health and allergy communities are paying more and more attention to the needs of food allergy families, and we are working hard to increase the number of mental health professionals who are equipped to do so."

SOURCE: https://bit.ly/2utQCOm Annals of Allergy, Asthma & Immunology, online February 25, 2020.

See original here:
Allergists Offer Advice to Parents of Kids With Food Allergies - The New York Times

Immunology

World Flow Cytometry Industry Outlook, 2020-2027 – Featuring Company Profiles for Agilent Technologies, Thermo Fisher Scientific, BD & Co,…

DUBLIN, Feb. 26, 2020 /PRNewswire/ -- The "Flow Cytometry Market by Product and Solution (Consumables, Instrument, Software, Service), Technology (Cell-based, Bead-based), Application (Cancer, Immunology, Hematology), and End-user (Pharmaceutical, Biotech, Academia) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global flow cytometry market is expected to grow at a CAGR of 8.2% from 2019 to 2027 to reach $6.36 billion by 2027.

The growth in the overall flow cytometry market is mainly attributed to rising global incidence and prevalence of chronic diseases, increasing adoption of flow cytometry techniques in research and academia, and growing initiatives in the field of immunology and immuno-oncology researches. In addition, evolving pipeline for stem cell research and adoption of recombinant DNA technology for antibody production will further provide significant opportunities for the various stakeholders in this market.

The overall flow cytometry market is mainly segmented by product and solution (instruments, software, accessories, services), technology (cell-based flow cytometry, bead-based flow cytometry), application (research, clinical, and industrial), end user (research and academic institutes, diagnostic laboratories, pharmaceutical & biotechnology companies), and geography.

On the basis of technology, bead-based technology segment is expected to grow at the highest CAGR during the forecast period. Procedural advantages offered by this technology over other cell-based technologies (such as ELISA and western blot), including its capacity to detect multiple analytes, high reproducibility, stability, and speed are expected to propel its growth.

On the basis of product and solution, the consumables and reagents segment accounted for the largest share of the overall flow cytometry market in 2019. Frequent utilization of application-specific reagents and assays by the end users is supporting the growth of this segment.

On the basis of application area, drug discovery segment held the largest share of the overall flow cytometry market in 2019. A wide variety of flow cytometry methods with the implementation of multi-parameter intracellular flow cytometric analysis have been employed at different stages of drug discovery and development. The growing demand for such advanced technologies used during drug discovery processes to simplify complicated cell analysis procedures is expected to drive the growth of this segment.

Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of this market in 2019. Increasing chronic cases leading to the development of new drugs and rise in R&D expenditure by companies is contributing to the growth of this segment.

An in-depth analysis of the geographical scenario of the flow cytometry market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America commanded the largest share of the global flow cytometry market in 2019, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The key players operating in the global flow cytometry market are Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Apogee Flow Systems Ltd. (U.K.), Sysmex Partec GmbH (Germany), Luminex Corporation (U.S.), Miltenyi Biotec GmbH (Germany), Bio-Rad Laboratories, Inc. (U.S.), bioMerieux S.A. (France), Cytonome/ST LLC (U.S.), Beckman Coulter, Inc. (U.S.), and Becton, Dickinson and Company (U.S.) among others.

Story continues

Key Topics Covered

1. Introduction1.1. Market Definition1.2. Market Ecosystem1.3. Currency1.4. Key Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Dynamics4.1. Introduction4.2. Drivers4.2.1. Rising Incidence and Prevalence of Chronic Diseases4.2.2. Growing Initiatives in the Field of Immunology and Immuno-Oncology Researches4.2.3. Adoption of Flow Cytometry Techniques in Research and Academia4.2.4. Flow Cytometry Based Technological Advancements4.3. Restraint4.3.1. Lack of Skilled Professionals4.4. Opportunities4.4.1. Growing Research Activities in Stem Cells4.4.2. Emerging Markets4.4.3. Adoption of Recombinant DNA Technology for Antibody Production4.5. Challenges4.5.1. Inadequate Research infrastructure across Emerging Countries4.5.2. Complexities Related to Reagent Development

5. Flow Cytometry Market, by Product & Solution5.1. Introduction5.2. Consumables and Reagents5.3. Instruments5.3.1. Cell Analyzers5.3.2. Cell Sorters5.4. Software5.5. Accessories5.6. Services

6. Flow Cytometry Market, by Technology6.1. Introduction6.2. Cell-Based Flow Cytometry6.3. Bead-Based Flow Cytometry

7. Flow Cytometry Market, by Application7.1. Introduction7.2. Research Applications7.2.1. Drug Discovery7.2.2. Stem Cell Research7.2.3. Immunology7.2.4. Cell Sorting7.2.5. Apoptosis7.2.6. Other Research Applications7.3. Clinical Applications7.3.1. Cancer7.3.2. Organ Transplantation7.3.3. Immunodeficiency Diseases7.3.4. Hematology7.3.5. Other Clinical Applications7.4. Industrial Applications

8. Flow Cytometry Market, by End-user8.1. Introduction8.2. Pharmaceutical & Biotechnology Companies8.3. Diagnostic Laboratories8.4. Research & Academic institutes

9. Global Flow Cytometry Market, by Geography9.1. Introduction9.2. North America9.2.1. U.S.9.2.2. Canada9.3. Europe9.3.1. Germany9.3.2. France9.3.3. U.K.9.3.4. Italy9.3.5. Spain9.3.6. Rest of Europe9.4. Asia-Pacific9.4.1. Japan9.4.2. China9.4.3. India9.4.4. Rest of Asia-Pacific9.5. Latin America9.6. Middle East & Africa

10. Competitive Landscape10.1. Introduction10.2. Key Growth Strategies10.3. Competitive Benchmarking10.4. Market Share Analysis (2018)

11. Company Profiles(Business Overview, Financial Overview, Product Portfolio, Strategic Developments)11.1. Agilent Technologies Inc.11.2. Thermo Fisher Scientific Inc.11.3. Becton, Dickinson & Company11.4. bioMerieux S.A.11.5. Beckman Coulter Inc. (Subsidiary of Danaher Corporation)11.6. Bio-Rad Laboratories Inc.11.7. Luminex Corporation11.8. Cytonome/St, LLC11.9. Apogee Flow Systems Ltd.11.10. Sysmex Partec GmbH (Subsidiary of Sysmex Corporation)11.11. Miltenyi Biotec B.V. & Co. KG

For more information about this report visit https://www.researchandmarkets.com/r/1mj41m

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/world-flow-cytometry-industry-outlook-2020-2027---featuring-company-profiles-for-agilent-technologies-thermo-fisher-scientific-bd--co-biomerieux-beckman-coulter-bio-rad-labs-and-more-301011564.html

SOURCE Research and Markets

More:
World Flow Cytometry Industry Outlook, 2020-2027 - Featuring Company Profiles for Agilent Technologies, Thermo Fisher Scientific, BD & Co,...

Immunology

Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience – Trefis

Roche Holdings(OTCMKTS:RHHBY) revenue grew at a CAGR of 5.3% from $52.5 billion in 2015 to $64.4 billion in 2019, and it is estimated to top $66 billion in 2020, led by its Neuroscience drugs. The companys oncology drugs will account for 45% of the companys total sales in 2020, but Neuroscience drugs are key to the near term revenue growth, in our view.Oncology drugs are expected to be the single-biggest revenue driver with $30.1 billion in revenues (45% of Total Revenues), which is 5.7x the size of its Neuroscience drugs revenue in 2020. Neuroscience drugs revenues, which includes Ocrevus and Modopar among other drugs, will be the fastest-growing segment adding $3.7 billion over 2017-2020 (32% of $11.6 billion in incremental revenues). Oncology drugs revenues, which includes Herceptin, Perjeta, Tecentriq, and Avastin among other drugs, will add about $3.4 billion over 2017-2020 (29% of the $11.6 billion in incremental revenue). Look at our interactive dashboard analysis on Roches Revenues for more details, parts of which are highlighted below.

Roches Revenue Has Been On A Rise Over The Last Few Years

Roche Has One of The Largest Oncology Drugs Portfolio, But It Is Expected To See A Decline Going Forward.

Ocrevus Has Been The Best Drug Launch Ever For Roche, Boosting Its Neuroscience Drugs Portfolio

Other Therapeutic Drugs Could Also See Growth In The Near Term

Among Other Segments, In-Vitro Diagnostics Could Continue To Grow At A Steady Pace, While Immunology, Ophthalmology, And Virology Drugs Could See A Decline

See allTrefis Price EstimatesandDownloadTrefis Datahere

Whats behind Trefis? See How Its Powering New Collaboration and What-Ifs ForCFOs and Finance Teams|Product, R&D, and Marketing Teams

Link:
Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience - Trefis

Immunology

Research Funding Available for Preeclampsia and Related Pregnancy Disorders – P&T Community

MELBOURNE, Fla., Feb. 26, 2020 /PRNewswire/ --The Preeclampsia Foundation announced that applications are now being accepted for its 2020 Vision Grant program.

The Preeclampsia Foundation will award up to two medical research Vision Grants to study preeclampsia and related hypertensive disorders of pregnancy, up to $20,000 USD each. The Foundation's Canadian affiliate, Preeclampsia Foundation Canada, will also award up to two Vision Grants up to $20,000 CAD each, to a Canadian researcher.

Vision Grants are intended to provide initial funding for novel, innovative research by promising young investigators that will advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy. Post-doctoral, Clinical Fellows, or Early Stage Investigators only are eligible to apply. Projects with potential to alter clinical management and improve patient outcomes will receive priority, but any well-considered research proposal will be accepted for review.International applications are welcome; however,submissions must be in English.

Application deadline is May 8, 2020, with award notification in August 2020. Instructions can be found at http://www.preeclampsia.org/research/research-funding (US) or http://www.preeclampsiacanada.ca (Canada).

Since its inception, the Preeclampsia Foundation's Vision Grant annual program has invested more than $550,000 in novel research ranging from molecular biology and immunology to potential therapies, with the goal of supporting new, potentially groundbreaking concepts. These results have, in turn, generated additional funding from the National Institutes of Health, earned scientific presentations at major conferences, and inspired young investigators to challenge a medical conundrum that has baffled the medical community for more than 2,400 years.

"We look forward to receiving diverse, quality applications again this year," said Dr. Thomas Easterling, director of the Preeclampsia Foundation's Medical Advisory Board. "There has been significant progress toward understanding preeclampsia during the past two decades, but there's much more research that needs to be done. We're pleased to be able to fuel this work through our Vision Grants for young investigators."

"It's exciting to be part of research and innovation that will lead to improved maternal and infant health and someday a cure," said Violet Mateljan, President of the Preeclampsia Foundation Canada Board of Directors."Preeclampsia Foundation Canada is very proud to be able to support a junior researcher with a Vision Grant in Canada."

About the Preeclampsia Foundation Vision Grant Award program:Funds medical research pertaining to the pathophysiology, diagnosis, and treatment of hypertensive disorders of pregnancy.

About the Preeclampsia Foundation: The Preeclampsia Foundation is a U.S.-based 501(c)(3) non-profit organization established in 2000. It is dedicated to providing patient support and education, raising public awareness, catalyzing research, and improving healthcare practices, envisioning a world where preeclampsia and related hypertensive disorders of pregnancy no longer threaten the lives of mothers and babies.For more information, visit http://www.preeclampsia.org.

About Preeclampsia Foundation Canada: Preeclampsia Foundation Canada was incorporated under the Canada Not-for-profit Corporations Act in May 2015. As an affiliate of the U.S. based Preeclampsia Foundation, its mission is to raise awareness and advance education and research of hypertensive disorders of pregnancy. For more information, visit http://www.preeclampsiacanada.ca.

Contact: Valerie Holloway (321) 421-6957 234909@email4pr.com

View original content:http://www.prnewswire.com/news-releases/research-funding-available-for-preeclampsia-and-related-pregnancy-disorders-301011676.html

SOURCE Preeclampsia Foundation

View post:
Research Funding Available for Preeclampsia and Related Pregnancy Disorders - P&T Community